louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06041113: Recurrent Extrahepatic Bile Duct Stones as a Late Complication of ERCP in Patients With Coexisting Intra- and Extrahepatic Bile Duct Stones
Official title: Recurrent Extrahepatic Bile Duct Stones as a Late Complication of ERCP in Patients With Coexisting Intra- and Extrahepatic Bile Duct Stones：a Long-term Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Intrahepatic Bile Duct Stone
Choledocholithiasis
Lead sponsor: Air Force Military Medical University, China
Sponsor class: OTHER
First posted: 2023-09-18
Enrollment: 104
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with intrahepatic and extrahepatic bile duct stones who underwent ERCP choledocholithotomy were eligible for our study

Brief summary: The management of coexisting intrahepatic bile duct (IBD) and extrahepatic bile duct (EBD) stones is complicated and requires a multidisciplinary approach. The long-term clinical outcomes of patients initially treated with endoscopic retrograde cholangiopancreatography (ERCP) EBD stone extraction remain unclear. Investigators conducted a retrospective study of patients with coexisting IBD and EBD to investigate the long-term impact of ERCP on the incidence of recurrent EBD stones and to identify risk factors of recurrence.


Eligibility criteria: Inclusion Criteria:

* non-gastrointestinal tract reconstruction patients with coexisting IBD and EBD stones who underwent ERCP between July 2008 and December 2020 at Xijing Hospital in China

Exclusion Criteria:

* patients with benign or malignant EBD strictures
* sclerosing cholangitis
* suspected choledochal cysts
* liver cirrhosis
* parasitic liver diseases
* long-term biliary drainage with biliary stents or percutaneous tubes
* without a definitive IBD stone or with a diagnosis of liver calcification as determined by imaging review
* medical records or follow-up information was unavailable

Primary outcomes:
measure: the recurrence rate of EBD stones
timeFrame: up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital of Digestive Diseases
state: Shaanxi
Study officials:
References:
citation: ASGE Standards of Practice Committee; Buxbaum JL, Abbas Fehmi SM, Sultan S, Fishman DS, Qumseya BJ, Cortessis VK, Schilperoort H, Kysh L, Matsuoka L, Yachimski P, Agrawal D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee JK, Naveed M, Sawhney MS, Thosani N, Yang J, Wani SB. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc. 2019 Jun;89(6):1075-1105.e15. doi: 10.1016/j.gie.2018.10.001. Epub 2019 Apr 9.
Clinical trial NCT01622413: Trial to Show Non-inferiority / Superiority of an Endoscopic Transforaminal Discectomy to Standard Microdiscectomy
Official title: Transforaminal Endoscopic Surgery Cost Outcome Research Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Lumbar Disc Herniation
Keywords: lumbar spine
herniated disc
slipped disc
disc herniation
discectomy
nucleotomy
disc surgery
endoscopy
spine
Lead sponsor: Joimax GmbH
Sponsor class: INDUSTRY
First posted: 2012-06-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares an endoscopic transforaminal surgical technique for the treatment of a herniated disc to the standard microsurgical procedure. Clinical parameters as well as health economy will be assessed.

The study hypothesis is that the endoscopic approach is equivalent or superior to microdiscectomy.


Eligibility criteria: Inclusion Criteria:

* symptomatic lumbar disc herniation
* clinical and radiological evidence of nerve root compression
* failure of conservative treatment for at least 6 weeks

Exclusion Criteria:

* previous lumbar spine surgery
* severe or progressive motor deficit
* BMI \> 40
* cauda equina syndrome

Primary outcomes:
measure: Change from baseline in Oswestry Disability Index at 4 years
timeFrame: total follow-up period of 4 years
Secondary outcomes:
measure: Change from baseline in Quality of Life (SF-12)
timeFrame: total follow-up period of 4 years
measure: Health resources consumption
timeFrame: total follow-up period of 4 years
measure: Complication rate
timeFrame: 2 years
measure: Patient satisfaction
timeFrame: Total follow-up period of 4 years
measure: Change from baseline in back and leg pain (NRS)
timeFrame: total follow-up period of 4 years
Other outcomes:
Locations:
city: Graz
country: Austria
facility: University Clinic of Neurosurgery
city: Frankfurt
country: Germany
facility: Ligamenta Spine Center
city: Heidelberg
country: Germany
facility: University Clinic Heidelberg, Department of Orthopedics, Traumatology and Paraplegiology
Study officials:
affiliation: University Clinic Heidelberg, Department of Orthopedics, Traumatology and Paraplegiology
name: Carl H Fürstenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03688113: Tinnitus Treatment Using a Smartphone Application
Official title: The Use of a Smartphone Application for Tinnitus Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tinnitus, Subjective
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-09-28
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: People with tinnitus will use a smartpphone app in which they are instructed to reject maladaptive thoughts by throwing them away from themselves (upwards) and embrace supportive thoughts by pulling them towards themselves (downwards). The Tinnitus Handicap Inventory will be used to measure the effect of the application.


Eligibility criteria: Inclusion Criteria:

* Tinnitus lasting more than 3 months

Exclusion Criteria:

* Brain space occupying lesion

Primary outcomes:
measure: Tinnitus Handicap Inventory score
timeFrame: 34 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tel-Aviv
country: Israel
facility: Sourasky Medical Center
Study officials:
References:
Clinical trial NCT06784713: DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN
Official title: DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID - 19
Diabetes Mellitus
Post-COVID Conditions
MIS-C Associated With COVID-19
Lead sponsor: University of Tartu
Sponsor class: OTHER
First posted: 2025-01-20
Enrollment: 127277
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All the Estonian children and adolescents (under 18 yo) who received COVID-19 diagnosis or positive SARS-CoV-2 test in a 3 year period

Brief summary: The study focuses on Estonian children under 18 who had COVID-19 from 27.02.2020 to 01.03.2023. The main aim is to find out the risk factors for severe COVID-19 in children. In order to do that the study includes their demographic data, vaccination status, and details about the severity of illness, such as hospitalization and long-term effects of COVID-19.

Detailed description: Data is collected for all children under 18 years old in Estonia who were diagnosed with COVID-19 between 27.02.2020 and 01.03.2024 (either with the ICD-10 codes U07.1/U07.2 and/or a positive SARS-CoV-2 test. The following data is collected for each patient: age at the time of COVID-19 diagnosis, gender, place of residence, and COVID-19 vaccination status.

In order to assess the severity of the disease, the following data is collected for each case: hospitalization due to COVID-19, length of hospitalization, need for intensive care, need for mechanical ventilation, fatal outcomes, and occurrence of long-term sequelae (post-COVID-19 condition and pediatric systemic inflammatory response syndrome). Additionally, data on any comorbid chronic and acute diseases of the children in the study group is collected. The outcome measures are compared across five different SARS-CoV-2 VOC periods: original, Alpha, Delta, Omicron BA.1/BA.2 and Omicron BA.4/BA.5.

Eligibility criteria: Inclusion Criteria:

* SARS-CoV-2 positivity or COVID-19 diagnosis (ICD-10 codes U07.1, U07.2)
* COVID-19 diagnosis in the following time period: 27/Feb/2020 to 01/Mar/2023

Exclusion Criteria:

* age above 18 years

Primary outcomes:
measure: Hospitalization due to COVID-19
timeFrame: From enrollment to the end of the observation period in Oct 2023
measure: Post-COVID condition
timeFrame: From enrollment to the end of the observation period in Oct 2023
measure: Diabetes mellitus
timeFrame: From enrollment to the end of the observation period in Oct 2023
measure: MIS-C
timeFrame: From enrollment to the end of the observation period in Oct 2023
measure: Mortality
timeFrame: From enrollment to the end of the observation period in Oct 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Tartu
country: Estonia
facility: University of Tartu
Study officials:
References:
Clinical trial NCT01840813: Intraumbilical Misoprostol in Retained Placenta
Official title: Intra-umbilical Injection of Misoprostol Versus Normal Saline in the Management of Retained Placenta: Intrapartum Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Retained Placenta
Keywords: Intraumbilical misoprostol
Retained placenta
Active management of third stage of labour
Lead sponsor: Hawler Medical University
Sponsor class: OTHER
First posted: 2013-04-26
Enrollment: 46
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Administration of intraumbilical misoprostol to women with retained placenta despite active management of third stage of labour reduces the need for manual removal of placenta and the amount of blood loss vaginally.

Detailed description: Retained placenta (RP)is one of the complications of third stage of labour; it should be managed promptly as it may cause severe bleeding, infection, maternal morbidity and mortality .The current standard management of RP word wide, by manual removal aims to prevent these problems, but it is unsatisfactory method because it requires general anaesthesia in hospital, It is an invasive procedure with its own serious complications of bleeding, infection and genital tract injury. Umbilical vein injection of misoprostol is a simple, safe method and could be performed at the place of delivery .

Eligibility criteria: Inclusion Criteria:

* women having singleton pregnancy
* 28 weeks of gestation or more delivered vaginally
* prolongation of the third stage of labour (more than 30 min) following active management of third stage of labour

Exclusion Criteria:

* Who refused to participate in the trial
* Multiple pregnancies
* Previous Caesarean Section
* Haemodynamically unstable
* Severe anaemia (haemoglobin less than 8gm/dl)
* Chorioamnionitis

Primary outcomes:
measure: delivery of placenta by medical intervention
timeFrame: 30 minutes after the injection of misoprostol or normal saline in the umbilical vein
Secondary outcomes:
measure: vaginal bleeding after misoprostol use
timeFrame: 30 minutes after umbilical vein injection of misoprostol
Other outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolabrity
timeFrame: 2 hours after umbilical vein injection of misoprostol
Locations:
city: Erbil city
country: Iraq
facility: Maternity Teaching Hospital
state: Kurdistan region
Study officials:
affiliation: Hawler Medical University
name: Shahla K. Alalaf, Clinical M.D
role: PRINCIPAL_INVESTIGATOR
affiliation: , Shaheed Dr.Khalid General Hospital, Directorate of Health
name: Sheelan S Rajab, High Diploma
role: STUDY_CHAIR
References:
Clinical trial NCT02732613: Selection of Laryngeal Mask Airway in Patients With Slender Somatotype
Official title: Selection of Laryngeal Mask Airway When Actual Body Weight Much Less Than Ideal Body Weight in Adult Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Size of Laryngeal Mask Airway
Body Weight
Success Rate of First Attempt
Complication
Keywords: Laryngeal Mask Airway
Body weight
Complication
Lead sponsor: Zhongshan People's Hospital, Guangdong, China
Sponsor class: OTHER
Collaborators: name: Sun Yat-sen University
First posted: 2016-04-08
Enrollment: 118
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The size selection of Laryngeal Mask Airway classic is usually followed the manufacturer's recommendation based on the patient's ideal weight. But sometimes the patient is tall and slim, the actual weight is much less than the ideal weight. This phenomenon might affect the success rate of insertion. Previous studies had demonstrated that the selection of Laryngeal Mask Airway size based on ideal weight could improve the success rate of insertion; therefore, this study was designed to prove whether this conclusion also applies to the tall and thin patients.

Detailed description: One hundred and eighteen patients adult patients，actual body weight much less than ideal body weight will be assigned randomly to two groups (Actual weight Group or Ideal weight Group). Size selection was guided by the recommendations of manufacturer, patients will be based on the actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.

The success rate of first attempt，number of adjustments, insertion time, ease of insertion, overall success rate, oropharyngeal leak pressure and fiberoptic view will be recorded and compared. The occurrences of respiratory complications such as sore throat, hoarseness, and dysphonia will be observed and recorded.

Eligibility criteria: Inclusion Criteria:

1. Adult Patients undergo elective surgery of American Society of Anesthesiologists (ASA) physical status 1-2, aged from 18 to 60;
2. Patients' actual weight much less than ideal weight.

Exclusion Criteria:

1. Patients with gastroesophageal reflux disease;
2. Patients with predicted difficult airway;
3. Patients with preexisting airway diseases or significant upper airway infection.

Primary outcomes:
measure: The success rate of Laryngeal Mask Airway first insertion
timeFrame: Six months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00890513: Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment
Official title: Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Illness
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
First posted: 2009-04-29
Enrollment: 1200
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Next of kin of patients cared for in one of the 42 ICU's located in german-speaking Switzerland (ICU recognized by Swiss Society of Intensive Care Medicine).

Brief summary: The primary aim of the present study is to assess satisfaction in a large sample of next of kin in Swiss-German ICUs.

Secondary aims are to test the hypothesis that family satisfaction is related to ICU structure and process and to factors related to patients and next of kin. Further, the hypothesis will be tested that proxy assessment is possible, i.e. next of kin rate satisfaction with care similar to patients.


Eligibility criteria: Inclusion Criteria:

* family members of patients staying for \> 48 hours in an ICU

Exclusion Criteria:

* lack of consent,
* insufficient knowledge of German language

Primary outcomes:
measure: To assess satisfaction in Swiss-German ICUs
Secondary outcomes:
measure: To test the hypothesis that family satisfaction is related to ICU structure and process To test the hypothesis that proxy assessment is possible
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Department of Intenisve Care Medicine, Inselspital
state: BE
Study officials:
affiliation: Bern University Hospital, University of Bern-Switzerland
name: Hans U Rothen, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Stricker KH, Kimberger O, Schmidlin K, Zwahlen M, Mohr U, Rothen HU. Family satisfaction in the intensive care unit: what makes the difference? Intensive Care Med. 2009 Dec;35(12):2051-9. doi: 10.1007/s00134-009-1611-4.
citation: Stricker KH, Kimberger O, Brunner L, Rothen HU. Patient satisfaction with care in the intensive care unit: can we rely on proxies? Acta Anaesthesiol Scand. 2011 Feb;55(2):149-56. doi: 10.1111/j.1399-6576.2010.02293.x. Epub 2010 Sep 6.
Clinical trial NCT05789836: The Effect of Partıcıpatıon in Care of Mothers
Official title: The Effect Of Participation in Care Of Mothers With Newborn Baby in Surgical Intensive Care On Mother's Self-Confidence And Mother-Infant Attachment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Newborn
Attachment
Self Confidence
Nursing Caries
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2023-03-29
Enrollment: 30
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This research was planned as a single group pretest-posttest quasi-experimental.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of the study is to examine the effect of including mothers with newborn babies in surgical intensive care units during the nursing care process on mother's self-confidence and mother-infant attachment.

Detailed description: Population and Sample of the Research

The population of the study consists of mothers who were hospitalized with their babies in the surgical intensive care unit in a children's hospital in Ankara (Turkiye). It is planned that the mothers who were hospitalized with their babies in the surgical intensive care unit for a period of 6 months between the dates of the study and who met the criteria for inclusion in the study constitute the sample of the study.

Eligibility criteria: Inclusion Criteria:

* Inpatient treatment of the baby in the surgical neonatal intensive care unit without the mother's presence since birth
* The mother stays with the baby for at least 4 days in the post-operative period
* The mother does not have any communication and language problems
* The mother's willingness to participate in the research

Exclusion Criteria:

-

Primary outcomes:
measure: Taylor Mother-Infant Attachment Scale
timeFrame: 6 month
measure: Pharis Self-Confidence Scale
timeFrame: 6 month
measure: Care Participation Assessment Scale
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Tokat Gaziosmanpasa University
state: Eyalet/Yerleşke
Study officials:
affiliation: Tokat Gaziosmanpasa University
name: Mukaddes Demir Acar
role: STUDY_CHAIR
References:
citation: Karakulak HA, Alparslan, Ö. Anne-bebek Bağlanma Ölçeğinin Türk Toplumuna Uyarlanması: Aydın Örneği. Çağdaş Tıp Dergisi. 2016; 6(3), 188-199.
citation: Karaçam Z, Çakmak E, Yenidoğan Yoğun Bakım Ünitesinde Bebeği Yatan Anneler İçin Bakıma Katılımı Değerlendirme Ölçeği: Ölçek Geliştirme, Geçerlilik ve Güvenilirliği. Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi. 2018; 21(2), 69-78.
Clinical trial NCT01055236: Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients
Official title: Hydroxyzine for the Prevention of Pruritus and Nausea Vomiting From Spinal Morphine in Patients Having Transabdominal Hysterectomy Under Combined Spinal-general Anesthesia: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pruritus
Nausea
Vomiting
Keywords: sedation
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2010-01-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Hydroxyzine is one of antihistamines that antagonizes H1 receptor, and it's effects are reducing pruritus, nausea/vomiting, and the mild effect of sedation.With these effects Hydroxyzine should be used in the prevention of these symptoms.

Detailed description: 80 patients scheduled for elective transabdominal hysterectomy under combined spinal-general anesthesia. they were randomized to receive either hydroxyzine 75 mg and midazolam 7.5 mg (ATR group) or placebo and midazolam 7.5 mg (control group) as premedication at least half an hour before operation. Clinical data (vital signs, pruritic score, nauseous score, sedation score, etc) was recorded at preoperative, intraoperative and 48-hour postoperative periods. All patients had spinal block with 0.5% heavy bupivacaine 2 ml with 0.3 mg preservative free morphine and general anesthesia with thiopental sodium 250-300 mg as induction, intubated with atracurium 0.6 mg/kg and maintenance with nitrous oxide, oxygen and isoflurane. Conventional reversal technique was done in all patients. Fentanyl intravenous was used for pain as needed, chlopheniramine syrup 2 tsp (4mg/10 ml) every 4 hours was used for pruritus and ondansetron intravenous (8 mg) was used for nausea/vomiting in postoperative period. The results were reported in number of patients or percent of patients who were suffered from pruritus, nausea, vomiting or sedation.

Eligibility criteria: Inclusion Criteria:

* ASA classification 1-2
* Age from 18-60 years old
* Body mass index (BMI) below 35
* Accepted combined spinal-general anesthesia

Exclusion Criteria:

* Previous history of Hydroxyzine allergy
* Underlying diseases of urticaria, pruritus, nausea vomiting and motion sickness
* Previous complications of procedure or anesthesia

Primary outcomes:
measure: successful treatment of pruritus
timeFrame: 48 hour
Secondary outcomes:
measure: successful treatment of nausea or vomiting
timeFrame: 48 hours
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Siriraj Hospital
state: Bangkok
Study officials:
affiliation: Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
name: Dr. Phuriphong Songarj, MD
role: STUDY_DIRECTOR
References: